drugset
drugset / Trial / NCT00617994

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

NCT00617994 ↗

Phase 2 Completed 25 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.

Timeline

Start
2007-08-31
Primary completion
2009-04-30
Completion
2009-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 1.5 % Topical

Indications

psoriasis